P-glycoprotein expression in patients with acute leukemia - Clinical relevance

Leukemia

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Nussler V ^a   Pelka Fleischer, R ^a   Zwierzina, H ^b   Nerl, C ^c   Beckert, B ^a   Gieseler, F ^d   Diem, H ^a   Ledderose, G ^a   Gullis, E ^e   Sauer, H ^a   Wilmanns, W ^a,e  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Klinikum Schwabing   (Germany)

^d Medizinische Poliklinik   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Acute leukemias; ALL; AML; MDR; P glycoprotein

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; GLYCOPROTEIN P; MONOCLONAL ANTIBODY; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; BLAST CELL; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 9444223257     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (72)

1. Büchner T, Hiddemann W, Koch P, Pielken H, Urbanitz D, Kreutzmann H, Maschmeyer G, Wendt F, Kuse R, Thiel E, Ludwig WD, Seibt H, Gassmann W, Löffler H, Aul C, Heyll A, Schneider W, Mertelsmann R, Anders CH, Nowrousian MR, Straif K, Vaupel HA, Hossfeld D. The role of maintenance chemotherapy; immunotherapy, induction dose reduction in elderly patients and double induction in the treatment of adult acute myeloid leukemia. 4 randomized studies of the AML Cooperative Group. Neue Therapeutische Strategien in der Hämatologischen Onkologie 1989; 36: 1-10.
2. Büchner T, Hiddemann W, Maschmeyer G, Ludwig W, Löffler H, Nowrousian M, Aul C, Heinecke A. How to improve therapy for adult acute myeloid leukemia. Studies of the AML-Cooperative-Group in the Federal Republic of Germany. J Cancer Res Clin Oncol 1990; 116: 97-99.
3. Jehn U, Zittoun R, Suciu S, Fiere D, Haanen C, Peetermans M, Löwenberg B, Willemze R, Solbu G, Stryckmans P, EORTC Leukemia Cooperative Group. A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy. AML-6 trial of the EORTC Leukemia Cooperative Group. Hemat Blood Transfus 1990; 33: 277-284.
4. Thiel E, Kranz BR, Raghavachar A, Bartram CR, Löffler H, Messerer D, Ganser A, Ludwig WD, Büchner T, Hölzer D. Prethymic phenotype and genotype of pre-T (CD7+/ER-) cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood 1989; 37: 1247-1258.
5. Hölzer D, Thiel E, Löffler H, Büchner T, Ganser A. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988; 71: 123-131.
6. Berman E, Heller G, Santorsa JA, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young Ch, Clarkson B. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991; 77: 1666-1674.
7. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized 1st line therapy. Leukemia 1990; 4: 184-188.
8. Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein is associated with multidrug-resistance in mammalian cells. Science 1983; 221: 1285-1288.
9. Gros P, Croop J, Roninson I, Varshavsky A, Houseman D. Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells. Proc Natl Acad Sci USA 1986; 83: 337-341.
10. Gottesman MM. How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53: 747-754.
11. Juranka PF, Zastawny RL, Ling V. P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 1989; 3: 2583-2592.
12. Ramu A, Ramu N, Rosario LM. Circumvention of multidrug-resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine. Biochem Pharmacol 1991; 41: 1455-1461.
13. Nooter K, Sonneveld P, Janssen A, Oostrum R, Boersma T, Herweijer H, Valerio D, Hagemeijer A, Baas F. Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. Int J Cancer 1990; 45: 626-631.
14. Ma DDF, Scurr RD, Davey RA, Mackertich SM, Harman DH, Dowden G, Isbister JP, Bell DR. Detection of a multidrug resistant phenotype in acute non-lymphoblastic leukemia. Lancet 1987; 1: 135-137.
15. Fojo AT, Ueda K, Salmon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multi-drug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-269.
16. Carulli G, Petrini M, Marini A, Ambrogi F. P-glycoprotein in acute lymphoblastic leukemia and in the blastic crisis of myeloid leukemia. New Engl J Med 1988; 319: 797-798.
17. Yau L, Li D, Tsao J, Kuo T, Savaraj N, Lu K. Expression of P-glycoprotein (MDR1) gene in patients with leukemia. Blood 1988; 72 (Suppl): 186-189.
18. Funato T, Bando Y, Kato H, Tokuhiro H, Shimoda Y, Ohtani H. Analysis of P-glycoprotein in patients with acute leukemias by flow cytometry. Rinsho-Byori 1989; 37: 779-783.
19. Goldstein JL, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human cancers. Cancer Inst 1989; 81: 116-124.
20. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua RA. Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukemia. Br J Haematol 1989; 72: 40-44.
21. Ito Y, Tanimoto M, Kumazawa T, Okumura M, Morishima Y, Ohno R, Saito H. Increased P-glycoprotein expression and multidrug-resistant gene (mdr1) amplification are frequently found in fresh acute leukemia cells. Cancer 1989; 63: 1534-1538.
22. Mattern J, Efferth T, Bak M, Ho AD, Volm M. Detection of P-glycoprotein in human leukemias using monoclonal antibodies. Blut 1989; 58: 215-217.
23. Rothenberg ML, Mickley LA, Cole DE, Balis FM, Tsuruo T, Poplack DG, Fojo AT. Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 1989; 74: 1388-1395.
24. Sugawara I, Kodo H, Ohkochi E, Hamada H, Tsuruo T, Mori S. High-level expression of MRK 16 and MRK 20 murine monoclonal antibody-defined proteins (170000-180000 P-glycoprotein and 85 000 protein) in leukemias and malignant lymphomas. Br J Cancer 1989; 60: 538-541.
25. Ball ED, Lawrence D, Malnar M, Ciminelli N, Mayer R, WursterHill D, Davey FR, Bloomfield CD. Correlation of CD34 and multidrug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML). Blood 1990; 76: 252a.
26. Carulli G, Petrini M, Marini A, Vaglini F, Cracciolo F, Grassi B. P-glycoprotein and drug resistance in acute leukemias and in the blastic crisis of chronic myeloid leukemia. Haematologica 1990; 75: 516-521.
27. Kato S, Nishimura J, Muta K, Yufu Y, Nawata H, Ideguchi H. Overexpression of P-glycoprotein in adult T-cell leukemia. Lancet 1990; 336: 118-119.
28. Kuwazuru Y, Hanada S, Furukawa T, Yoshimura A, Sumizawa T, Utsonomiya A, Ishibashi K, Saito T, Uozumi K, Maruyama M, Ishizawa M, Arima T, Akiyama S. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990; 76: 2065-2071.
29. Kuwazuru Y, Yoshimura A, Hanada S, Utsonomiya A, Makino T, Ishibashi K, Kodama M, Iwahashi M, Arima T, Akiyama S. Expression of the multidrug transporter, P-glycoprotein, in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990; 66: 868-873.
30. Musto P, Cascavilla N, Di Renzo N, Ladogana S, La-Sala A, Melillo L, Nibile M, Matera R, Lombardi G, Carotenuto M. Clinical relevance of immunocytochemical detection of multidrug-resistance-associated P-glycoprotein in haematological malignancies. Tumori 1990; 76: 353-359.
31. Nooter K, Sonneveld P, Oostrum R, Herweijer H, Haganbeek T, Valerio D. Overexpression of the mdr1 gene in blast cells from patients and acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int J Cancer 1990; 45: 263-268.
32. Redner A, Hegewisch S, Haimi J, Steinherz P, Jhanwar S, Andreff M. A study of multidrug resistance and cell kinetics in a child with near-haploid acute lymphoblastic leukemia. Leukemia Res 1990; 14: 771-777.
33. Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA, Preisler HD. Expression of the multidrug resistance gene in myeloid leukemias. Leukemia Res 1990; 14: 11-21.
34. Chitnis M, Hedge U, Chavan S, Juvekar A, Advani S. Expression of the multidrug transporter P-glycoprotein and in vitro chemosensitivity: correlation with in vivo response to chemotherapy in acute myeloid leukemia. Sel Cancer Ther 1991; 7: 165-173.
35. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 79: 586-592.
36. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol 1991; 77: 50-53.
37. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L. MDR1 gene expression and treatment outcome in acute myeloid leukaemia. J Natl Cancer Inst 1991; 83: 708-712.
38. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992; 79: 473-476.
39. Campos L, Guyotat D, Jaffar C, Solary E, Archimbaud E, Treille D. Correlation of MDR/P-170 expression with daunorubicin uptake and sensitivity of leukemic pregenitors in acute myeloid leukemia. Eur J Haematol 1992; 48: 254-258.
40. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S, Tsuruo T, Grandi M, Baccarani M, Tura S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia, Eur J Haematol 1992; 48: 87-92.
41. Tiirikainen MI, Syrjälä MT, Jansson SE, Krusius T. Flow cytometric analysis of P-glycoprotein in normal and leukemic cells. Ann Hematol 1992; 65: 124-130.
42. Gruber A, Vitols S, Norgren S, Aresttom I, Peterson C, Bjorkholm M, Reizenstein P, Luthman H. Quantative determination of mdr1 gene expression in leukaemic cells from patients with acute leukemia. Br J Cancer 1992; 66: 266-272.
43. Zhou DC, Marie JP, Suberville AM, Zittoun R. Relevance of mdr-1 gene expression in acute myeloid leukaemia and comparison of different diagnostic methods. Leukemia 1992; 6: 879-885.
44. Willman CL, Kopecky KJ, Weick J, Applebaum F, Grever MR, Head DR, Elias L, Balcerzak SP, Mills GM, Hynes HE. Biologic parameters that predict treatment response in de novo acute myeloid leukaemia (AML): CD34 but not multidrug resistance (mdr) gene expression is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside. Proc ASCO 1992; 11: 262-267.
45. Wittebol S, Te Boekhorst P, Hagemelier A, Van Dongen JJM, Schoester M, Sonneveld P. Expression of the multidrug resistance (MDR-1) phenotype in acute myelocytic leukaemia is associated with CD34 expression and monosomy 7 and predicts for poor survival. Blood 1992; 80: 202a.
46. Wood P, Liu Yin JA, Burgess R. P-glycoprotein expression in adult acute leukaemias: correlation with treatment outcome. Proc ISH 1992, p 54.
47. Goasguen JE, Dossot JM, Fardel O, Le Mee F, Le Gall E, Leblay R, Leprise PY, Chaperon J, Fauchet R. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81: 2394-2398.
48. Miyachi H, Takemura Y, Yonekura S, Komatsuda M, Nagao T, Arimori S, Ando Y. MDR1 (multidrug resistance) gene expression in adult acute leukemia: correlations with blast phenotype. Int J Hematol 1993; 57: 31-37.
49. Hegewisch-Becker S, Fliegener M, Tsuruo T, Zeller W, Hossfeld DK. Multidrug resistance (mdr1) in adult acute leukemia at diagnosis: correlation with response to induction chemotherapy. Onkologie 1993; 16: 264-268.
50. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820-823.
51. Georges E, Bradley G, Cariepy J, Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 152-156.
52. Schinkel AH, Roelofs MEM, Borst P. Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies. Cancer Res 1991; 51: 2628-2635.
53. Dixon AR, Bell J, Ellis IO, Elston CW, Blarney RW. P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy. Br J Cancer 1992; 66: 537-541.
54. Finstad CL, Yin BWT, Gordon CM, Federeci MG, Welt S, Lloyd KO. Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis. J Histochem Cytochem 1991: 39: 1603-1610.
55. Arceci RJ, Stieglitz K, Bras J, Schinkel A, Baas F, Croop J. Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Res 1993; 53: 310-317.
56. Gekeler V, Frese G, Noller A, Handgretinger R, Willisch A, Schmidt H, Muller CP, Dopfer R, Klingebiel T, Diddens H, Probst H, Niethammer D. Mdr1/P-glycoprotein, topoisomerase and glutathione-S-transferase Pl expression in primary and relapsed state adult and childhood leukemias. Br J Cancer 1992; 66: 507-517.
57. Moscow JA, Fairchild CR, Madden MJ, Ransom DT, Wieand HS, O'Brien EE, Poplack DG, Cossman J, Myers CE, Cowan KH. Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989; 49: 1422-1428.
58. Beck WT. Mechanisms of multidrug resistance in human tumor cells: the roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat Rev 1990; 17: 11-20.
59. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane-bound glycoprotein. Cancer Res 1993; 53: 3658-3661.
60. Nooter K, Sonneveld P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leukemia Res 1994; 18: 233-243.
61. Cornwall MM. The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Diff 1990; 1: 607-615.
62. Quantin B, Breathnach R. Epidermal growth factor stimulates transcription of the c-jun proto-oncogene in rat fibroblasts. Nature 1988; 334: 538-539.
63. Tanaguchi H, Pyerin W. Glutathione-S-transferase is an in vitro substrate of Ca++-phospholipid-dependent protein kinase (protein kinase C). Biochem Biophys Res Commun 1989; 162: 903-907.
64. Chambers TC, McAvoy EM, Jakobs JW, Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J Biol Chem 1990; 265: 7679-7686.
65. Teeter ED, Eckersberg T, Tsai Y, Kuo MT. Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Diff 1991; 2: 429-437.
66. Nakagawa M, Schneider E, Dixon KH, Horten J, Kelley K, Morrow Ch, Cowan KH. Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells. Cancer Res 1992; 52: 6175-6181.
67. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, Ganapathi R. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 1992; 44: 937-945.
68. Volm M. P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. Anticancer Res 1993; 13: 375-378.
69. Efferth T, Volm M. Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance. Cancer Detect Prevent 1992; 16: 237-243.
70. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992; 79: 3267-3273.
71. Nüssler V, Gieseler F, Pelka-Fleischer R, Gullis E, Zwiezina H, Bartl R, Abenhard W, Schmitt R, Langenmayer I, Heinemann V, Kolb HJ, Wilmanns W. Pilot study with idarubicin monotherapy: response of multiply pretreated leukemia patients. Ann Haematol (submitted).
72. Grunicke H, Überall F. Protein kinase C modulation. Semin Cancer Biol 1992; 3: 351-360.